Cancer focus Targeted opportunity to engage for collaboration or licensing in oncology drug development leveraging Myrexis pipeline with potential first-in-class or best-in-class mechanisms; align messaging with clinical differentiation and novel chemistries.

Mid-market scale Company size and revenue position it as a nimble partner for co-development, out-licensing, or strategic collaborations with large pharma, offering faster cycles and focused resource allocation compared to mega-cap competitors.

Clinical and preclinical Opportunity to propose staged collaboration across preclinical to clinical assets, enabling milestone-driven deals and early access to innovative candidates that can complement or expand your oncology portfolio.

Tech-enabled ops Leverage their modern tech stack and cloud capabilities to propose joint digital health or data-driven trial solutions, including analytics, cloud collaboration, and scalable infrastructure for research operations.

Strategic fit signals Position as a partner capable of accelerating development timelines and de-risking early-stage programs, with emphasis on potential first-in-class therapies that can fill gaps in larger company portfolios.